Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

730 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-molecular-weight heparin and mortality in acutely ill medical patients.
Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF; LIFENOX Investigators. Kakkar AK, et al. Among authors: goldhaber sz. N Engl J Med. 2011 Dec 29;365(26):2463-72. doi: 10.1056/NEJMoa1111288. N Engl J Med. 2011. PMID: 22204723 Free article. Clinical Trial.
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ; PREVENT Investigators. Ridker PM, et al. Among authors: goldhaber sz. N Engl J Med. 2003 Apr 10;348(15):1425-34. doi: 10.1056/NEJMoa035029. Epub 2003 Feb 24. N Engl J Med. 2003. PMID: 12601075 Free article. Clinical Trial.
Rationale and design of a clinical trial of a low-molecular-weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study).
Vaitkus PT, Leizorovicz A, Goldhaber SZ; PREVENT Investigator Group. Vaitkus PT, et al. Among authors: goldhaber sz. Vasc Med. 2002;7(4):269-73. doi: 10.1191/1358863x02vm449oa. Vasc Med. 2002. PMID: 12710842 Clinical Trial.
Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S; ODIXa-DVT Study Investigators. Agnelli G, et al. Among authors: goldhaber sz. Circulation. 2007 Jul 10;116(2):180-7. doi: 10.1161/CIRCULATIONAHA.106.668020. Epub 2007 Jun 18. Circulation. 2007. PMID: 17576867 Clinical Trial.
Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; RE-COVER Study Group. Schulman S, et al. Among authors: goldhaber sz. N Engl J Med. 2009 Dec 10;361(24):2342-52. doi: 10.1056/NEJMoa0906598. N Engl J Med. 2009. PMID: 19966341 Free article. Clinical Trial.
730 results